Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Rametta

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Neurology and Therapy|December 16, 2017
Vitamin D and Multiple Sclerosis: A Comprehensive ReviewMartina B Sintzel, Mark Rametta, Anthony T Reder
Neurology and Therapy|December 15, 2015
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)Tjalf Ziemssen, Lauren Sylvester, Mark Rametta, et al.
International Journal of MS Care|January 24, 2014
The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START StudySuhayl Dhib-Jalbut, Clyde Markowitz, Payal Patel, et al.
Neurology and Therapy|January 22, 2022
A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-InjectorRyan Farej, Mark Rametta, Anneliese La Rose, et al.
Neurology and Therapy|June 10, 2016
Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical AutoinjectorsDonald A Barone, Barry A Singer, Lubo Merkov, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosisAnthony T Reder, Joel F Oger, Ludwig Kappos, et al.
Journal of Neuroimmunology|September 25, 2012
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START studySuhayl Dhib-Jalbut, Sumandeep Sumandeep, Reuben Valenzuela, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
Sentiment of Media Coverage and Reputation of the Pharmaceutical IndustryValentina Pampulevski, Jessica R Giaquinto, Mark Rametta, et al.
Drugs - Real World Outcomes|April 30, 2021
Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT<sup>®</sup> Autoinjector: A Retrospective Cohort StudyOisín Butler, Simone Heeg, Katsiaryna Holl, et al.
BMJ Open|December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b studyDouglas S Goodin, George C Ebers, Gary Cutter, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Neurology and Therapy|December 16, 2017
Vitamin D and Multiple Sclerosis: A Comprehensive ReviewMartina B Sintzel, Mark Rametta, Anthony T Reder
Neurology and Therapy|December 15, 2015
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)Tjalf Ziemssen, Lauren Sylvester, Mark Rametta, et al.
International Journal of MS Care|January 24, 2014
The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START StudySuhayl Dhib-Jalbut, Clyde Markowitz, Payal Patel, et al.
Neurology and Therapy|January 22, 2022
A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-InjectorRyan Farej, Mark Rametta, Anneliese La Rose, et al.
Neurology and Therapy|June 10, 2016
Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical AutoinjectorsDonald A Barone, Barry A Singer, Lubo Merkov, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosisAnthony T Reder, Joel F Oger, Ludwig Kappos, et al.
Journal of Neuroimmunology|September 25, 2012
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START studySuhayl Dhib-Jalbut, Sumandeep Sumandeep, Reuben Valenzuela, et al.
Therapeutic Innovation & Regulatory Science|February 3, 2020
Sentiment of Media Coverage and Reputation of the Pharmaceutical IndustryValentina Pampulevski, Jessica R Giaquinto, Mark Rametta, et al.
Drugs - Real World Outcomes|April 30, 2021
Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT<sup>®</sup> Autoinjector: A Retrospective Cohort StudyOisín Butler, Simone Heeg, Katsiaryna Holl, et al.
BMJ Open|December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b studyDouglas S Goodin, George C Ebers, Gary Cutter, et al.
Pageof 1